First experience of the third generation titanium-nitride-oxide bioactive stent Titan Optimax: a new horizon in angioplasty

With an unrestricted educational grant from HEXACATH

Learning Objectives

  • To evaluate the clinical results of the third generation titanium-nitride-oxide bioactive stent
  • To appreciate the clinical performances of titanium-nitride-oxide bioactive stents together with the best performing DES
  • To review the latest data available on titanium-nitride-oxide coated stents

Presentations available when logged in:

  • Introduction and objectives
  • The BASE-ACS (827 patients) randomised trial comparing the titanium-nitride-oxide bioactive Titan2 stent with the everolimus-eluting stent Xience V...
  • The TIDES-OCT (40 patients) randomised multicentric study comparing Optimax titanium-nitride-oxide coated stent versus the Promus Element stent
  • The TIDES-ACS (1800 patients) study rationale: a randomised multicentric study comparing Optimax titanium-nitride-oxide-coated stent versus the Syn...
  • The OPTIMAX-FIM (120 patients) registry and OPTIMAX-QCA study (late loss at 6 months)
  • The TITAN-AMI (1113 patients) multicentric registry evaluating the usage of Titan2 in AMI patients
  • The BALAD (543 patients) registry: bioactive stent in the left anterior descending artery
  • Take-home message